Recombinant FSH (follitropin alpha)
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ovulation Induction
Conditions
Ovulation Induction
Trial Timeline
Mar 1, 2009 → Mar 1, 2011
NCT ID
NCT01081626About Recombinant FSH (follitropin alpha)
Recombinant FSH (follitropin alpha) is a approved stage product being developed by Merck for Ovulation Induction. The current trial status is completed. This product is registered under clinical trial identifier NCT01081626. Target conditions include Ovulation Induction.
What happened to similar drugs?
2 of 4 similar drugs in Ovulation Induction were approved
Approved (2) Terminated (2) Active (2)
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01081626 | Approved | Completed |
Competing Products
13 competing products in Ovulation Induction